RenovoRx Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) The following documents are filed as part of this Annual Report on Form 10-K
1. Financial Statements
| Page | |
| Financial Statements for the Years Ended December 31, 2023 and 2022 | |
|---|---|
| Report of Independent Registered Public Accounting Firm Baker Tilly US, LLP (PCAOB Firm ID 23) | F-1 |
| Balance Sheets | F-2 |
| Statements of Operations and Comprehensive Loss | F-3 |
| Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) | F-4 |
| Statements of Cash Flows | F-5 |
| Notes to Financial Statements | F-6 |
2. Financial Statement Schedules
All financial statement schedules have been omitted because the required information is not applicable or is not present in amounts sufficient to require submission of the schedules, or because the information required is included in the financial statements and accompanying notes included in this Report.
3. Exhibits
See “Exhibit Index” immediately preceding the signature page of this Report, which is incorporated herein by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.